In September 2016, a cooperation project signing ceremony was held at Qingdao International Academician Park. Academician Wang Yutian signed the cooperation agreement with the Director of the Management Committee of Qingdao International Academician Park, marking the official establishment of the first innovative drug research institute founded by Academician Wang Yutian and a team of renowned overseas academicians—Qingdao Primedicine Pharmaceutical Technology Co., Ltd., which aims to transform scientific research results into practical and marketable applications.

In November 2016, the company acquired the “Methods for modulating neuronal response using inhibitors of AMPA receptor endocytosis” patent from the University of British Columbia in Canada. The company will use the patented method to develop innovative drugs for treating drug addiction, Alzheimers disease, cerebral stroke, depression, and other diseases.

In March 2017, the launch ceremony of Academician Wang Yutians innovative drug research institute was held at Building 12 of Qingdao International Academician Park. Wang Xijing, Secretary of Licang District Party Committee and the main leaders from Licang District Party Committee and the local government attended the event.

In May 2017, the PMS-001 project (GluA2 Subtype AMPA receptor modulator) officially commenced pre-clinical work in accordance with the regulations of the National Measures for the Administration of New Drug Research Registration, marking a significant step in the process of transforming pharmaceutical research.

In August 2017, the company acquired the “N-methyl-D-aspartate receptor (NMDAR) allosteric modulators” patent, from the University of British Columbia in Canada, which was initially declared in the United States. The company filed the PCT international patent application in September and is now the patent owner. The company aims to use the patent to develop innovative drugs for treating cerebral stroke, Alzheimers disease, schizophrenia, and other diseases.

In November 2017, the company acquired the authorization and the global exclusive right to use the “Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum” patent, from the University of Saskatchewan in Canada. The company will use the patent to develop drugs for acne and weight loss, as well as to develop and commercialize a cosmetics product line for oil control and acne suppression.

In November 2018, the application for a new indication patent for “Depression treatment methods and drugs”, which the company submitted to the China Patent Office for PMS-001 depression treatment, was accepted.

In May 2019, the companys Drug Research Center was officially operational. The Center is located on the 3rd and 4th floors and covers an area of 1,200 square meters. It consists of four centers or experimental areas, namely, a drug screening center, an analysis and testing center, a drug efficacy evaluation center, and a quality research center.

In July 2019, the company established Lanpu Medical Technology (Changchun) Co., Ltd. in cooperation with Lanpu Biotechnology Co., Ltd. and Beijing UnderProved Medical Technology Co., Ltd. to jointly promote high-level development of domestic cosmetics business.

In September 2019, all preclinical studies on PMS-001 for treating drug addiction were completed. The Pre-IND application for PMS-001 (Indication: Drug Addiction) was submitted to the National Drug Examination Center.

In April 2020, the company submitted the PMS-001 (Indication: Stroke) Pre-IND application to the National Drug Examination Center for the development of the PMS-001 stroke indication project.

In April 2020, the company obtained the exclusive authorization for the Chinese market from Primary Peptides Inc. The PMS-004 (Indication: Myocardial Infarction) project was officially made operational.